Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.80%
)
US TECH 100
26,538.40
(
1.85%
)
Dow Jones
49,247.66
(
-0.13%
)
Brent Oil
100.66
(
0.00%
)
Bitcoin
77,549.84
(
-0.09%
)
News Focus
News Focus
Post# of 517593
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

circa1762

Send PM Follow Ignore
Followers 16
Posts 825
Boards Moderated 0
Alias Born 02/01/2012

circa1762

Re: WellSpring post# 53611

Thursday, 02/11/2016 5:50:08 PM

Thursday, February 11, 2016 5:50:08 PM

Post# of 517593
The great thing is Alzheimer's trials are short compared to cancer trials, so with or without breakthrough designation, starting a Phase 2b/3 trial this year means it should finish sometime in 2017, right after which 2-73 could potentially move to commercialization if results repeat what we are seeing in the 2a trial.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News